{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:20:36Z","timestamp":1762017636025},"reference-count":27,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            While the pharmacokinetic (PK) properties of daptomycin in hemodialysis (HD) patients have been evaluated previously by three groups, resultant dosing recommendations have varied. To address this clinical conundrum, this study combined concentration-time data from these PK evaluations and derived uniform dosing recommendations among patients on HD receiving daptomycin. A two-compartment model with separate HD and non-HD clearance terms was fit to the PK data from these studies by using BigNPAG. Embedded with PK parameters from the population PK analysis, 5,000-subject Monte Carlo simulations (MCS) were performed to identify HD dosing schemes that provided efficacy (cumulative and daily area under the concentration-time curve [AUC] values) and toxicity (trough concentrations of \u226524.3 mg\/liter) profiles comparable to those from simulations employing the daptomycin PK model derived from the\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            bacteremia\u2013infective endocarditis (SAB-IE) study. Separate HD dosing schemes were sought for the two weekly interdialytic periods (48 and 72 h). For the 48-h interdialytic period, intra- and post-HD dosing provided the most isometric cumulative and daily AUCs. For the 72-h interdialytic period, all HD dosing schemes provided noncumulative AUC values from 48 to 72 h (AUC\n            <jats:sub>48\u201372<\/jats:sub>\n            ) that were &lt;50% of the SAB-IE AUC\n            <jats:sub>48\u201372<\/jats:sub>\n            values. Increasing the parent dose by 50% intra- or post-HD provided comparable AUC\n            <jats:sub>48\u201372<\/jats:sub>\n            values, while maintaining acceptable trough concentration (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>min<\/jats:sub>\n            ) values. When efficacy and toxicity profiles were evaluated for each individual study, higher probabilities for\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>min<\/jats:sub>\n            reaching \u226524.3 mg\/liter were observed in one of the three studies. Given the high probability of\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>min<\/jats:sub>\n            being \u226524.3 mg\/liter in one of the three studies, more intensive creatine phosphokinase (CPK) monitoring may be warranted in HD patients receiving daptomycin.\n          <\/jats:p>","DOI":"10.1128\/aac.02000-12","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T14:01:14Z","timestamp":1354629674000},"page":"864-872","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis"],"prefix":"10.1128","volume":"57","author":[{"given":"Jill M.","family":"Butterfield","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Mueller","sequence":"additional","affiliation":[{"name":"University of Michigan College of Pharmacy, Department of Clinical, Social and Administrative Sciences, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie E.","family":"Cardone","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren W.","family":"Grabe","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha N.","family":"Salama","sequence":"additional","affiliation":[{"name":"St. Louis College of Pharmacy, St. Louis, Missouri, USA"},{"name":"Cairo University Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"United States Renal Data System. 2010. USRDS 2008 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Bethesda MD."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)01078-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000286347"},{"key":"e_1_3_3_5_2","first-page":"197","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients\u2014United States, 2005","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","unstructured":"Centers for Disease Control and Prevention. 2007. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients\u2014United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 56:197\u2013199.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2011.00999.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1073-4449(96)80022-7"},{"key":"e_1_3_3_8_2","volume-title":"Cubicin (daptomycin for injection) (full prescribing information).","author":"Cubist Pharmaceuticals","year":"2010","unstructured":"Cubist Pharmaceuticals. 2010. Cubicin (daptomycin for injection) (full prescribing information). Cubist Pharmaceuticals, Lexington, MA."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2000.00337.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mic.2002.120904"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01650309"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp655"},{"key":"e_1_3_3_13_2","first-page":"63","article-title":"Pharmacokinetics and safety of multiple doses of daptomycin 6 mg\/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis","volume":"75","author":"Benziger DP","year":"2011","unstructured":"BenzigerDP PertelPE DonovanJ YankelevS SchwabRJ SwanSK CannonC. 2011. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg\/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin. Nephrol. 75:63\u201369.","journal-title":"Clin. Nephrol."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01224-10"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/652767"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1109\/CBMS.2001.941750"},{"key":"e_1_3_3_18_2","volume-title":"ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software.","author":"D'Argenio DZ","year":"2009","unstructured":"D'ArgenioDZ SchumitzkyA WangX. 2009. ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp289"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg337"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.845-851.2001"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.63-68.2004"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/647938"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2948-2953.2000"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2010.05.007"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.5.562"},{"key":"e_1_3_3_27_2","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","author":"KDOQI, National Kidney Foundation","year":"2006","unstructured":"KDOQI, National Kidney Foundation. 2006. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 47:S11\u2013S145.","journal-title":"Am. J. Kidney Dis."},{"key":"e_1_3_3_28_2","volume-title":"National health statistics reports, no. 10.","author":"McDowell MA","year":"2008","unstructured":"McDowellMA FryarCD OgdenCL FlegalKM. 2008. Anthropometric reference data for children and adults: United States, 2003-2006. National health statistics reports, no. 10. National Center for Health Statistics, Hyattsville, MD."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02000-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02000-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:21:51Z","timestamp":1645482111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02000-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1128\/AAC.02000-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.02000-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"2012-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-11-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}